Open AccessEffect of Short-Time BelAgeTM Prescription on Pregnancy and Risk Preeclampsia
Author(s) -
Alejandra Lisbeth Rodríguez Zamora,
José Anaya Herrera,
Fanny Palma Navarrete,
Hugo Mendieta Zerón
Publication year - 2022
Publication title -
yemeni journal for medical sciences
Language(s) - English
Resource type - Journals
eISSN - 2227-961X
pISSN - 2227-9601
DOI - 10.20428/yjms.15.1.a3
Subject(s) - preeclampsia , medicine , blood pressure , pregnancy , confidence interval , relative risk , obstetrics , medical prescription , randomized controlled trial , diastole , prospective cohort study , gynecology , genetics , pharmacology , biology
The aim was to determine if one month taking BelAgeTM in the second trimester of pregnancy could reduce the risk of preeclampsia.Methods: From April 2019 to July 2020, a non-blinded, prospective, randomized, study was performed inviting women in the second trimester of pregnancy to take 3 g of BelAgeTM once daily for one month. The control group received only the nutritional assessment. Relative risk (RR) to develop preeclampsia with 95% confidence interval (CI) was calculated using the Social Science Statistics online software, considering a significant statistical value a P-value < 0.05.Results: 144 patients from the BelAgeTM group (mean age 23.6 ± 9.7), and 99 from the control group (mean age 22.1 ± 8.6) were included, finding differences basal systolic blood pressure (P = 0.03), final diastolic blood pressure (P = 0.002) and final mean blood pressure (P = 0.001). Preeclampsia was developed by 18 patients in the BelAgeTM group versus ten patients in the control group, RR 1.2 (95% CI, 0.60–2.57, P = 0.57).Conclusion: A short-time BelAgeTM prescription in the second trimester of pregnancy was enough to reduce the DBP, but did not reduce the risk of developing preeclampsia.Keywords: BelAgeTM diastolic blood pressure, preeclampsia, relative risk.